Archives
![](https://cholangiocarcinoma.org/wp-content/uploads/2024/04/Five-for-Friday-nocovid-transbg-300x300.png)
Five for Friday – 5 ways you can get involved in Awareness Month
Home / Blog / [wpbb post:title] During the month of February, we invite everyone to participate in Awareness Month, with…
![](https://cholangiocarcinoma.org/wp-content/uploads/2024/04/Five-for-Friday-nocovid-transbg-300x300.png)
Five for Friday – 5 clinical trials presented at GI ASCO
Home / Blog / [wpbb post:title] The American Society of Clinical Oncology Gastrointestinal Cancers Symposium (GI ASCO) recognizes the important…
![](https://cholangiocarcinoma.org/wp-content/uploads/2024/04/15-years-logo-300x200.png)
Cholangiocarcinoma Foundation Celebrates 15th Anniversary Milestone
FDA Approves Incyte's Pemazyre™ (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma…
![](https://cholangiocarcinoma.org/wp-content/uploads/2024/04/Five-for-Friday-nocovid-transbg-300x300.png)
Five for Friday – 5 takeaways from GI ASCO
Home / Blog / [wpbb post:title] The American Society of Clinical Oncology Gastrointestinal Cancers Symposium (GI ASCO) is an annual…
![](https://cholangiocarcinoma.org/wp-content/uploads/2024/04/noun_hand-shake_3128801-300x300.png)
Cholangiocarcinoma Foundation Launches Trusted Partners Program
FDA Approves Incyte's Pemazyre™ (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma…
![](https://cholangiocarcinoma.org/wp-content/uploads/2024/04/Five-for-Friday-nocovid-transbg-300x300.png)
Five for Friday – 5 reasons why you should participate in research with Ciitizen
Home / Blog / [wpbb post:title] You are the future of research, and we want you to know that your…
![](https://cholangiocarcinoma.org/wp-content/uploads/2024/04/Five-for-Friday-nocovid-transbg-300x300.png)
Five for Friday – 5 events to add to your calendar as we begin the new year
Home / Blog / [wpbb post:title] We hope you had a Happy New Year! Exciting things are happening at Cholangiocarcinoma…
![](https://cholangiocarcinoma.org/wp-content/uploads/2024/04/Five-for-Friday-nocovid-transbg-300x300.png)
Five for Friday – 5 impactful ways you can make a year-end gift
Home / Blog / [wpbb post:title] As 2020 comes to a close, there are a number of opportunities to support…
![](https://cholangiocarcinoma.org/wp-content/uploads/2024/04/Five-for-Friday-nocovid-transbg-300x300.png)
Five for Friday – 5 ways you can get involved with the 2021 Annual Conference
Home / Blog / [wpbb post:title] We are so excited that the 8th Annual Cholangiocarcinoma Foundation Conference is around the…
Cholangiocarcinoma Foundation celebrates FDA’s Breakthrough Therapy Designation for Zanidatamab in Patients with Biliary Tract Cancer
The Cholangiocarcinoma Foundation (CCF) celebrates the November 30, 2020 FDA breakthrough therapy designation for Zanidatamab in patients with previously-treated HER2…
![](https://cholangiocarcinoma.org/wp-content/uploads/2024/04/Five-for-Friday-nocovid-transbg-300x300.png)
Five for Friday – 5 ways you can get involved in Candles for the Cure
Home / Blog / [wpbb post:title] This holiday season, we are asking everyone to take part in our annual year-end…
Cholangiocarcinoma Foundation celebrates FDA’s Acceptance Of New Drug Application For Infigratinib For The Treatment Of Cholangiocarcinoma
On behalf of patients and families impacted by cholangiocarcinoma, the Cholangiocarcinoma Foundation (CCF) celebrates the December 1, 2020 FDA acceptance…